R-GemOx
Phase 2Small molecule
R-GemOx is one of 44 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in Phase 2.
1
Indications
5
Total Trials
4
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
332 competitors in Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Eloxatin
TevaPhase 3
Rayos
RRoxane Laboratories
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
COLUMVI
RochePhase 3
Cytosar
TevaPhase 3
Vepesid
AAvyxa
Phase 3
Adcetris
PfizerPhase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
Imbruvica
PPharmacyclics LLC.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed/Refractory2 trials
Elderly1 trial
AZA Combined with R-GemOx for Elderly DLBCL Patients
Not yet recruiting·—·Phase 2·NCT06778902·80 enrolled
Elderly Patients1 trial
Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT01670370·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for R-GemOx. EMBL-EBI & Wellcome Sanger Institute.
- [4]